Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma (NCT06561048)
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- City of Hope National Medical Center — Duarte, California
- University of California, Irvine — Irvine, California
- University of California San Francisco — San Francisco, California
- Yale University — New Haven, Connecticut
- Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine — Miami, Florida
- Emory University — Atlanta, Georgia
- North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- University of Maryland Medical Center — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Roger Cancer Center University of Michigan Health — Ann Arbor, Michigan
- Washington University in St. Louis — St Louis, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medicine — New York, New York
- North Carolina Cancer Hospital — Chapel Hill, North Carolina
- The Ohio State University — Columbus, Ohio
- MD Anderson Cancer Center — Houston, Texas
- University of Washington Fred Hutch Cancer Center — Seattle, Washington
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
- St Vincent's Hospital Sydney — Darlinghurst, New South Wales
- St George Hospital — Kogarah, New South Wales
- ICON Cancer Centre — South Brisbane, Queensland
- Royal Adelaide Hospital — Adelaide, South Australia
📞 Contact the Study Coordinator
Phone: (650) 900-4520
Email: clinicaltrials@corvuspharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Peripheral T-Cell Lymphoma, Not Otherwise Specified clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.